Your browser doesn't support javascript.
loading
Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers.
Cui, Yingzi; Cui, Dongyang; Ren, Xinran; Chen, Xuesong; Liu, Guangwen; Liu, Zhengzhi; Wang, Yanli; Qu, Xinyao; Zhao, Yicheng; Yang, Haimiao.
Afiliação
  • Cui Y; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
  • Cui D; Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China.
  • Ren X; Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China.
  • Chen X; School of Pharmacy, Jilin University, Jilin, China.
  • Liu G; Clinical Medical College, Changchun University of Chinese Medicine, Jilin, China.
  • Liu Z; Jilin Province Honesty Medical Technology Consulting Co., Ltd., Jilin, China.
  • Wang Y; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
  • Qu X; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
  • Zhao Y; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
  • Yang H; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
Front Pharmacol ; 13: 907413, 2022.
Article em En | MEDLINE | ID: mdl-35600852
ABSTRACT
[This corrects the article DOI 10.3389/fphar.2021.660541.].
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China